Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-Controlled Studies (vol 36, pg 1130, 2014)

被引：0
|
作者：
Lehrke, M.
机构：
来源：
CLINICAL THERAPEUTICS | 2014年 / 36卷 / 11期
关键词：
D O I：
10.1016/j.clinthera.2014.10.017
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1705 / 1705
页数：1
相关论文
共 50 条
  • [1] Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
    Lehrke, Michael
    Marx, Nikolaus
    Patel, Sanjay
    Seck, Thomas
    Crowe, Susanne
    Cheng, Karen
    von Eynatten, Maximilian
    Johansen, Odd Erik
    CLINICAL THERAPEUTICS, 2014, 36 (08) : 1130 - 1146
  • [2] Safety and tolerability of linagliptin in 7400 patients with type 2 diabetes: a pooled comprehensive analysis of prospective safety reporting in placebo-controlled studies
    Lehrke, M.
    Marx, N.
    Patel, S.
    Seck, T.
    Crowe, S.
    von Eynatten, M.
    Johansen, O.
    DIABETOLOGIA, 2013, 56 : S395 - S395
  • [3] Safety of linagliptin in 8778 patients with type 2 diabetes mellitus: pooled analysis of 23 placebo-controlled randomised clinical trials
    Schernthaner, G.
    Khunti, K.
    Patel, S.
    Cheng, K.
    Mattheus, M.
    Woerle, H. -J.
    DIABETOLOGIA, 2014, 57 : S360 - S360
  • [4] Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials
    Kanasaki, Keizo
    Qu, Shen
    Yamamoto, Fumiko
    Schepers, Cornelia
    Simoes, Rafael Sani
    Yabe, Daisuke
    Ji, Linong
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (03) : 425 - 434
  • [5] Safety and Tolerability of Linagliptin: A Pooled Analysis of Data from 3572 Patients with Type 2 Diabetes
    Schernthaner, Guntram
    Von Eynatten, Maximilian
    Emser, Angela
    Patel, Sanjay
    Woerle, Hans J.
    DIABETES, 2011, 60 : A619 - A619
  • [6] Safety and tolerability of empagliflozin in patients with type 2 diabetes and advanced kidney disease: a large pooled analysis of placebo-controlled trials
    Levin, A.
    Nangaku, M.
    Kadowaki, T.
    Tuttle, K.
    Hauske, S.
    Zeller, C.
    Kohler, S.
    von Eynatten, M.
    Wanner, C.
    DIABETOLOGIA, 2017, 60 : S85 - S85
  • [7] Safety of Linagliptin in 8,778 Patients with Type 2 Diabetes Mellitus: Pooled Analysis of 23 Placebo-Controlled, Randomized Clinical Trials
    Schernthaner, Guntram
    Khunti, Kamlesh
    Patel, Sanjay
    Cheng, Karen
    Mattheus, Michaela
    Woerle, Hans-Juergen
    DIABETES, 2014, 63 : A281 - A281
  • [8] Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
    Schernthaner, G.
    Barnett, A. H.
    Emser, A.
    Patel, S.
    Troost, J.
    Woerle, H. -J.
    von Eynatten, M.
    DIABETES OBESITY & METABOLISM, 2012, 14 (05): : 470 - 478
  • [9] Comprehensive Analysis of Safety Data Pooled from 22 Randomized Controlled Trials of Linagliptin in Patients with Type 2 Diabetes Mellitus with or without Renal Impairment
    von Eynafteni, Maximilian
    Lehrke, Michael
    Marx, Nikolaus
    Patel, Sanjay
    Seck, Thomas
    Crowe, Susanne
    Johansen, Odd Erik
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [10] Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
    Davidson, Jaime A.
    Lajara, Rosemarie
    Aguilar, Richard B.
    Mattheus, Michaela
    Woerle, Hans-Juergen
    von Eynatten, Maximilian
    BMJ OPEN DIABETES RESEARCH & CARE, 2014, 2 (01):
12345